<?xml version='1.0' encoding='utf-8'?>
<document id="15545312"><sentence text="Metabolism by N-acetyltransferase 1 in vitro and in healthy volunteers: a prototype for targeted inhibition." /><sentence text="Inhibition of drug metabolism is generally avoided but can be useful in limited circumstances, such as reducing the formation of toxic metabolites" /><sentence text=" Acetylation is a major pathway for drug elimination that can also convert substrates into toxic species, including carcinogens" /><sentence text=" Sulfamethoxazole, a widely used antibiotic, is metabolized via arylamine N-acetyltransferase 1"><entity charOffset="1-17" id="DDI-PubMed.15545312.s4.e0" text="Sulfamethoxazole" /><entity charOffset="64-73" id="DDI-PubMed.15545312.s4.e1" text="arylamine" /><pair ddi="false" e1="DDI-PubMed.15545312.s4.e0" e2="DDI-PubMed.15545312.s4.e0" /><pair ddi="false" e1="DDI-PubMed.15545312.s4.e0" e2="DDI-PubMed.15545312.s4.e1" /></sentence><sentence text=" p-Aminosalicylate, used for antitubercular treatment, is also metabolized by N-acetyltransferase 1 and could potentially inhibit sulfamethoxazole metabolism"><entity charOffset="1-18" id="DDI-PubMed.15545312.s5.e0" text="p-Aminosalicylate" /><entity charOffset="130-146" id="DDI-PubMed.15545312.s5.e1" text="sulfamethoxazole" /><pair ddi="false" e1="DDI-PubMed.15545312.s5.e0" e2="DDI-PubMed.15545312.s5.e0" /><pair ddi="false" e1="DDI-PubMed.15545312.s5.e0" e2="DDI-PubMed.15545312.s5.e1" /></sentence><sentence text=" Human hepatocytes from 4 donors were incubated in vitro with sulfamethoxazole and paminosalicylate at clinically achievable concentrations"><entity charOffset="62-78" id="DDI-PubMed.15545312.s6.e0" text="sulfamethoxazole" /><entity charOffset="83-99" id="DDI-PubMed.15545312.s6.e1" text="paminosalicylate" /><pair ddi="false" e1="DDI-PubMed.15545312.s6.e0" e2="DDI-PubMed.15545312.s6.e0" /><pair ddi="false" e1="DDI-PubMed.15545312.s6.e0" e2="DDI-PubMed.15545312.s6.e1" /></sentence><sentence text=" p-Aminosalicylate competitively reduced the acetylation of sulfamethoxazole in vitro by 61% to 83% at 200 microM"><entity charOffset="1-18" id="DDI-PubMed.15545312.s7.e0" text="p-Aminosalicylate" /><entity charOffset="60-76" id="DDI-PubMed.15545312.s7.e1" text="sulfamethoxazole" /><pair ddi="false" e1="DDI-PubMed.15545312.s7.e0" e2="DDI-PubMed.15545312.s7.e0" /><pair ddi="false" e1="DDI-PubMed.15545312.s7.e0" e2="DDI-PubMed.15545312.s7.e1" /></sentence><sentence text=" Four healthy volunteers were studied following doses of 500 mg sulfamethoxazole either alone or during administration of paminosalicylate (4 g ter in die)"><entity charOffset="64-80" id="DDI-PubMed.15545312.s8.e0" text="sulfamethoxazole" /><entity charOffset="122-138" id="DDI-PubMed.15545312.s8.e1" text="paminosalicylate" /><pair ddi="false" e1="DDI-PubMed.15545312.s8.e0" e2="DDI-PubMed.15545312.s8.e0" /><pair ddi="false" e1="DDI-PubMed.15545312.s8.e0" e2="DDI-PubMed.15545312.s8.e1" /></sentence><sentence text=" Plasma concentrations of paminosalicylate exceeded 100 microM"><entity charOffset="26-42" id="DDI-PubMed.15545312.s9.e0" text="paminosalicylate" /></sentence><sentence text=" With each subject as his or her own control, p-aminosalicylate reduced by 5-fold the ratio of plasma concentrations of acetylsulfamethoxazole relative to parent drug (P &lt; "><entity charOffset="46-63" id="DDI-PubMed.15545312.s10.e0" text="p-aminosalicylate" /><entity charOffset="120-142" id="DDI-PubMed.15545312.s10.e1" text="acetylsulfamethoxazole" /><pair ddi="false" e1="DDI-PubMed.15545312.s10.e0" e2="DDI-PubMed.15545312.s10.e0" /><pair ddi="false" e1="DDI-PubMed.15545312.s10.e0" e2="DDI-PubMed.15545312.s10.e1" /></sentence><sentence text="001)" /><sentence text=" Metabolic drug-drug interaction studies in vitro successfully predicted inhibition of acetylation via N-acetyltransferase 1 in vivo" /><sentence text=" Although no specific toxic species was investigated in this work, the potential was demonstrated for improving the therapeutic index of drugs that have toxic metabolites" /><sentence text="" /></document>